Fumaric acid ester treatment in cutaneous lupus erythematosus (CLE): A prospective, open-label, phase II pilot study

Lupus

Volumn 25, Issue 12, 2016, Pages 1357-1364

  Kuhn, Annegret ^a,b   Landmann, A ^b   Patsinakidis, N ^c   Ruland, V ^d   Nozinic, S ^b   Perusquia Ortiz A M ^d   Sauerland, C ^e   Luger, T ^d   Tsianakas, A ^d   Bonsmann, G ^d  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c KLINIKUM BREMEN MITTE   (Germany)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

alternative treatment; clinical trial; Cutaneous lupus erythematosus; fumaric acid esters; RCLASI

Indexed keywords

AMINOTRANSFERASE; FUMADERM; FUMARIC ACID DIMETHYL ESTER; FUMARIC ACID ETHYL ESTER; SUNSCREEN; FUMARIC ACID DERIVATIVE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; ARTICLE; ASSESSMENT OF HUMANS; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENTERIC COATED TABLET; ERYTHEMA; FEMALE; HEADACHE; HUMAN; MALE; MIDDLE AGED; NAUSEA; OPEN STUDY; PATIENT ASSESSMENT; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVISED CUTANEOUS LUPUS DISEASE AREA AND SEVERITY INDEX; SIDE EFFECT; SKIN DEFECT; SKIN LUPUS ERYTHEMATOSUS; TACHYCARDIA; TREATMENT OUTCOME; VOMITING; CHEMICALLY INDUCED; CLINICAL TRIAL; COLIC; DRUG ADMINISTRATION; LUPUS ERYTHEMATOSUS, CUTANEOUS; SEVERITY OF ILLNESS INDEX;

ADULT; COLIC; DRUG ADMINISTRATION SCHEDULE; FEMALE; FUMARATES; HEADACHE; HUMANS; LUPUS ERYTHEMATOSUS, CUTANEOUS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84988734882     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203316644335     Document Type: Article

References (21)

1. Jarukitsopa S, Hoganson DD, Crowson CS, et al. Epidemiology of systemic lupus erythematosus and cutaneous lupus erythematosus in a predominantly white population in the United States. Arthritis Care Res 2015; 67: 817-828.
2. Kuhn A, Ruland V, Bonsmann G,. Cutaneous lupus erythematosus: Update of therapeutic options part I. J Am Acad Dermatol 2011; 65: e179-e193.
3. Kuhn A, Ruland V, Bonsmann G,. Cutaneous lupus erythematosus: Update of therapeutic options part II. J Am Acad Dermatol 2011; 65: e195-e213.
4. Winkelmann RR, Kim GK, Del Rosso JQ,. Treatment of cutaneous lupus erythematosus: Review and assessment of treatment benefits based on Oxford Centre for Evidence-based Medicine Criteria. J Clin Aesthet Dermatol 2013; 6: 27-38.
5. Wenzel J, Brähler S, Bauer R, et al. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: Results of a retrospective study in 43 patients. Br J Dermatol 2005; 153: 157-162.
6. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23 (Suppl 2): 1-70.
7. Mrowietz U, Rostami-Yazdi M, Neureither M, et al. 15 years of Fumaderm: Fumaric acid esters for the systemic treatment of moderately severe and severe psoriasis vulgaris [article in German]. J Dtsch Dermatol Ges 2009; 7 (Suppl 2): S3-S16.
8. Walker F, Adamczyk A, Kellerer C, et al. Fumaderm® in daily practice for psoriasis: Dosing, efficacy and quality of life. Br J Dermatol 2014; 171: 1197-1205.
9. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012; 367: 1098-1107.
10. Mrowietz U, Asadullah K,. Dimethylfumarate for psoriasis: More than a dietary curiosity. Trends Mol Med 2005; 11: 43-48.
11. Gerdes S, Shakery K, Mrowietz U,. Dimethylfumarate inhibits nuclear binding of nuclear factor kappaB but not of nuclear factor of activated T cells and CCAAT/enhancer binding protein beta in activated human T cells. Br J Dermatol 2007; 156: 838-842.
12. Meissner M, Valesky EM, Kippenberger S, et al. Dimethyl fumarate-only an anti-psoriatic medication? J Dtsch Dermatol Ges 2012; 10: 793-801.
13. Bacharaçh-Buhles M, Röchling A, el Gammal S, et al. The effect of fumaric acid esters and dithranol on acanthosis and hyperproliferation in psoriasis vulgaris. Acta Derm Venereol 1996; 76: 190-193.
14. Balak D, Thio HB,. Treatment of lupus erythematosus with fumaric acid esters: two case-reports. J Transl Med 2011; 9 (Suppl 2): 15-15.
15. Klein A, Coras B, Landthaler M, et al. Off-label use of fumarate therapy for granulomatous and inflammatory skin diseases other than psoriasis vulgaris: A retrospective study. J Eur Acad Dermatol Venereol 2012; 26: 1400-1406.
16. Tsianakas A, Herzog S, Landmann A, et al. Successful treatment of discoid lupus erythematosus with fumaric acid esters. J Am Acad Dermatol 2014; 71: e15-e17.
17. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
18. Kuhn A, Meuth AM, Bein D, et al. Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): A modified outcome instrument for cutaneous lupus erythematosus. Br J Dermatol 2010; 163: 83-92.
19. Carlin CS, Feldman SR, Krueger JG, et al. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 2004; 50: 859-866.
20. Jessop S, Whitelaw DA and Delamere FM. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev 2009: CD002954.
21. Reich K, Thaci D, Mrowietz U, et al. Efficacy and safety of fumaric acid esters in the long-term treatment of psoriasis-a retrospective study (FUTURE) [article in English, German]. J Dtsch Dermatol Ges 2009; 7: 603-611.